Pharma Journalist -

AbbVie and RemeGen have entered into an exclusive global licensing agreement aimed at advancing RC148, a novel investigational bispecific antibody targeting both Programmed Cell Death-1…
Read More...

AbbVie and West Pharmaceutical Services have announced a definitive agreement under which AbbVie will acquire a device manufacturing facility and associated intellectual property from…
Read More...

Fortress Biotech, Inc. and its majority-owned subsidiary Cyprium Therapeutics have received a major regulatory milestone with the U.S. Food and Drug Administration’s approval of ZYCUBO®…
Read More...

BD (Becton, Dickinson and Company), a global leader in medical technology, has announced a $110 million investment to expand its production of prefillable syringes in the United States,…
Read More...

Solid Biosciences Inc., a life sciences company focused on developing precision genetic medicines for neuromuscular and cardiac diseases, has reached two important milestones in the…
Read More...

Synaffix B.V., a Lonza company, and Sidewinder Therapeutics have entered into a multi-target licensing agreement aimed at developing first-in-class bispecific antibody-drug conjugate…
Read More...

Alessa Therapeutics has received Fast Track designation from the U.S. Food and Drug Administration for Enolen®, its lead investigational therapy for the treatment of low- to…
Read More...

Cellenkos Inc., a clinical-stage biotechnology company developing off-the-shelf regulatory T cell (Treg) therapies, has received Orphan Drug Designation from the U.S. Food and Drug…
Read More...

Santhera Pharmaceuticals has signed an exclusive licensing agreement with Nxera Pharma UK to develop, manufacture, and commercialize AGAMREE® (vamorolone) for the treatment of Duchenne…
Read More...

Eli Lilly and Company has reported positive topline results from its novel TOGETHER-PsA Phase 3b trial, demonstrating that the concomitant use of Taltz (ixekizumab) and Zepbound…
Read More...